Announced details
Integration, standardization and consistency checks for SOPs and quality documents at pharmaceutical companies, medical device manufacturers, contract manufacturing organizations (CMOs), CROs and other organizations
株式会社ロゼッタ and ONO PHARMACEUTICAL CO.,LTD. jointly developed the service. Joint development began in June 2025.
Head office: Chuo-ku, Osaka; Representative Director and President: Takino Toichi (滝野 十一). Other company information: Not disclosed.
3 plans: Light, Standard and Premium. Contact the company for detailed pricing.
The impact on the financial results of MetaReal Corporation is minor
The company does not address Contract Value.
ITR, “ITR Market View: Generative AI/Machine Learning Platform Market 2025”
| Item | Details |
|---|---|
| Names of Products / Services Covered | Rakuyaku SOP Editor, an AI service for integrating and standardizing SOPs, Rakuyaku AI |
| Counterparty | ONO PHARMACEUTICAL CO.,LTD. |
| Counterparty overview | Head office: Chuo-ku, Osaka; Representative Director and President: Takino Toichi (滝野 十一). Other company information: Not disclosed. |
| Relationship with the Company | 株式会社ロゼッタ and ONO PHARMACEUTICAL CO.,LTD. jointly developed the service. Joint development began in June 2025. |
| Offering price | 3 plans: Light, Standard and Premium. Contact the company for detailed pricing. |
| Launch date | 15 May 2026 (official release; actual) |
| Applicable area | Integration, standardization and consistency checks for SOPs and quality documents at pharmaceutical companies, medical device manufacturers, contract manufacturing organizations (CMOs), CROs and other organizations |
| Impact on Business Performance | The impact on the financial results of MetaReal Corporation is minor |
| Source | ITR, “ITR Market View: Generative AI/Machine Learning Platform Market 2025” |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To address the growing burden of reconciling and integrating SOPs at pharmaceutical companies and inconsistencies among documents, while supporting greater operational efficiency and standardization through AI.